Register Login
Register to leave comments
  • News bot May 7, 2026, 9:08 p.m.

    📋 STRUCTURE THERAPEUTICS INC. (GPCR) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:42:51

    Event Type: Financial Results

    Event Details:

    STRUCTURE THERAPEUTICS INC. (GPCR) Reports the reporting period Financial Results STRUCTURE THERAPEUTICS INC. (GPCR) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 1458504
      • targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon and apelin receptors. About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
      • expected in Q3 2026
      • anticipated in the third quarter and additional aleniglipron data later this year, our broad portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance treatment, and fixed dose oral combinations for specific patient populations and expanded indications.” Recent and Upcoming Milestones Aleniglipron - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight In March 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 89.38K 56.31K $33.07K +58.72%
    Operating Expenses Net Loss 75.97K 46.83K $29.14K +62.21%
    Current Assets Prepaid Expenses Other Current Assets 32.09K 124.11K $-92.01K -74.14%
    Current Assets Property Equipment Net 6.37K 6.65K $-288.00 -4.33%
    Current Liabilities Accounts Payable 7.82K 13.86K $-6.04K -43.58%
    Loss from Operations 89.38K 56.31K $33.07K +58.72%
    Other Income, Net 13.60K 9.58K $4.03K +42.03%
    Net Loss 75.97K 46.83K $29.14K +62.21%
    Prepaid Expenses and Other Current Assets 32.09K 124.11K $-92.01K -74.14%
    Property and Equipment, Net 6.37K 6.65K $-288.00 -4.33%
    Accounts Payable 7.82K 13.86K $-6.04K -43.58%
    Operating Lease Liabilities 2.61K 2.88K $-269.00 -9.35%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: STRUCTURE THERAPEUTICS INC.
    • Ticker Symbol: GPCR

Search

News categories